Filed with the SEC as Trieu Vuong; the order above is the one the filer's own signature uses.
In the 12 months to Nov 8, 2026, on the open market: bought $60K of OTLC. Filed a median of 1 business day after the trade.
Open-market purchases and sales this filer reported on SEC Form 4, by the day traded. Insiders have two business days to file. A sale marked 10b5-1 was made under a plan adopted in advance. How to read these
Insider purchases above the line: $60KInsider sales below: $0
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.
OTLCBought: Oncotelic Therapeutics, Inc. Oct 29, 20261,044,990 sharesfiled Oct 30, 202695,481,309 shares held directly after, as filedfiling$18K
OTLCBought: Oncotelic Therapeutics, Inc. Oct 28, 2026312,000 sharesfiled Oct 30, 202694,436,319 shares held directly after, as filedfiling$6K
OTLCBought: Oncotelic Therapeutics, Inc. Jul 1, 2026240,000 sharesfiled Jul 2, 202694,124,319 shares held directly after, as filedfiling$10K
OTLCBought: Oncotelic Therapeutics, Inc. Jun 24, 2026115,000 sharesfiled Jun 24, 202693,884,319 shares held directly after, as filedfiling$5K
OTLCBought: Oncotelic Therapeutics, Inc. Jun 23, 202675,000 sharesfiled Jun 24, 202693,769,319 shares held directly after, as filedfiling$3K
OTLCBought: Oncotelic Therapeutics, Inc. Jun 22, 202665,000 sharesfiled Jun 24, 202693,694,319 shares held directly after, as filedfiling$3K
OTLCBought: Oncotelic Therapeutics, Inc. Jun 17, 2026239,759 sharesfiled Jun 17, 202693,629,319 shares held directly after, as filedfiling$11K
OTLCBought: Oncotelic Therapeutics, Inc. Jun 15, 202696,000 sharesfiled Jun 17, 202693,389,560 shares held directly after, as filedfiling$4K
Source: SEC Form 4 filings. Value is shares × the price reported on the filing; a filing whose price failed Lytir's check against the market price is left out, and a trade that related owners reported on separate forms is counted once. Filings can be late, amended or wrong at the source; see methodology.
